Life Sciences  •  London  •  Early Stage

DefiniGEN is a spinout from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development.


Total BGF investment


Investment date

November 2020

Head office


Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.
Dr Marcus Yeo , CEO